IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Bio Medica Laboratories Ltd.
Issue Open Date 21-May-26  
Issue Closing Date 25-May-26  
Application Money 100  
Allotment Money  
Price Band 132 - 139  
Minimium Application No. 2000  
Issue Size (Shares) 3772000  
Market Lot 1.00  
Objective
1. To meet out the Repayment of Loan;2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at theexisting premises3. To meet out the General Corporate Purposes
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors     2475000   NA  
Qualified Institutional Buyers     574000   NA  
Retail Individual Investors     5228000   NA  
Business Description
Our Company is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. We manufacturevariety of products, comprising ethical drugs, generic drugs and over the-counter drugs (OTC) in the form ofinjectables namely Liquid Injections and Dry Powder
more...
Promoter's Holding
Total Share Capital   8889909  
Offered to Public   3772000  
Promoter's Holding (Pre-Issue)   96.84  
Promoter's Holding (Post-Issue)   67.69  
Address
Plot No. 11 B-11 C
Sector- E
Sanwer Road
Industrial Area
Industrial Estate
Indore ,
Madhya Pradesh ,
452015
Phone: 7314102751
Email: companysecretary@biomedica.co.in
Website: www.biomedica.co.in
Registrar
Skyline Financial Services Pvt Ltd
123
Vinoba Puri
Lajpat Nagar - II

New Delhi
Listed at
NSE
Lead Manager
Narnolia Financial Services Ltd.
Promoters
Mukesh Mehta
Pradeep Mehta
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Scores| Policies of JFSL
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE| Rights and obligation| SARAL Form
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.